Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial

BACKGROUND: The ECHELON-2 5-year update showed continued clinically meaningful improvements in progression-free survival (PFS) and overall survival with frontline (1L) A+CHP (brentuximab vedotin in combination with cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, John M, Yu, Kristina S, Mordi, Uche, Bloudek, Brian, Liu, Nicholas, Phillips, Tycel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387925/
https://www.ncbi.nlm.nih.gov/pubmed/36840956
http://dx.doi.org/10.18553/jmcp.2023.29.3.314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387925/
https://www.ncbi.nlm.nih.gov/pubmed/36840956
http://dx.doi.org/10.18553/jmcp.2023.29.3.314

Ejemplares similares